Terms: = Leukemia AND IL2, IL-2, 3558, ENSG00000109471, P60568
2463 results:
1. Interleukin-2 is required for NKp30-dependent NK cell cytotoxicity by preferentially regulating NKp30 expression.
Kim N; Yi E; Lee E; Park HJ; Kim HS
Front Immunol; 2024; 15():1388018. PubMed ID: 38698855
[TBL] [Abstract] [Full Text] [Related]
2. Exercise-induced β2-adrenergic Receptor Activation Enhances the Antileukemic Activity of Expanded γδ T-Cells via DNAM-1 Upregulation and PVR/Nectin-2 Recognition.
Baker FL; Smith KA; Mylabathula PL; Zúñiga TM; Diak DM; Batatinha H; Niemiro GM; Seckeler MD; Pedlar CR; O'Connor DP; Colombo J; Katsanis E; Simpson RJ
Cancer Res Commun; 2024 May; 4(5):1253-1267. PubMed ID: 38592213
[TBL] [Abstract] [Full Text] [Related]
3. Ponatinib and STAT5 Inhibitor Pimozide Combined Synergistic Treatment Applications Potentially Overcome Drug Resistance via Regulating the Cytokine Expressional Network in Chronic Myeloid leukemia Cells.
Tezcanli Kaymaz B; Gumus N; Celik B; Alcitepe İ; Biray Avci C; Aktan C
J Interferon Cytokine Res; 2024 Apr; 44(4):178-189. PubMed ID: 38579140
[TBL] [Abstract] [Full Text] [Related]
4. Discovery of 5-aminopyrido[2,3-d]pyrimidin-7(8H)-one derivatives as new hematopoietic progenitor kinase 1 (HPK1) inhibitors.
Qiu X; Liu R; Ling H; Zhou Y; Ren X; Zhou F; Zhang J; Huang W; Wang Z; Ding K
Eur J Med Chem; 2024 Apr; 269():116310. PubMed ID: 38479166
[TBL] [Abstract] [Full Text] [Related]
5. [Study on the Effect and Mechanism of Tetrandrine on Bone Marrow Mesenchymal Stem Cell-Mediated Drug Resistance in leukemia].
Zhou XY; Jin N; Chen BA
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):33-38. PubMed ID: 38387896
[TBL] [Abstract] [Full Text] [Related]
6. [Immune Reconstitution after BTKi Treatment in Chronic Lymphocytic leukemia].
Wang YL; Tang PX; Chen KL; Guo GY; Long JL; Zou YQ; Liang HY; Xu ZS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):1-5. PubMed ID: 38387891
[TBL] [Abstract] [Full Text] [Related]
7. [Durable remission of T-cell prolymphocytic leukemia with CLEC16A::il2 after allogeneic hematopoietic stem cell transplantation].
Momose H; Kurita N; Nishikii H; Yusa N; Yokoyama K; Shimizu E; Imoto S; Nanmoku T; Maruyama Y; Sakamoto T; Yokoyama Y; Kato T; Matsuoka R; Obara N; Sakata-Yanagimoto M; Chiba S
Rinsho Ketsueki; 2024; 65(1):35-40. PubMed ID: 38311387
[TBL] [Abstract] [Full Text] [Related]
8. Development of Innate-Immune-Cell-Based Immunotherapy for Adult T-Cell leukemia-Lymphoma.
Nakashima M; Tanaka Y; Okamura H; Kato T; Imaizumi Y; Nagai K; Miyazaki Y; Murota H
Cells; 2024 Jan; 13(2):. PubMed ID: 38247820
[TBL] [Abstract] [Full Text] [Related]
9. Bone marrow-derived mesenchymal stromal cells obstruct AML-targeting CD8
Towers R; Trombello L; Fusenig M; Tunger A; Baumann AL; Savoldelli R; Wehner R; Fasslrinner F; Arndt C; Dazzi F; Von Bonin M; Feldmann A; Bachmann MP; Wobus M; Schmitz M; Bornhäuser M
Cancer Immunol Immunother; 2024 Jan; 73(1):8. PubMed ID: 38231344
[TBL] [Abstract] [Full Text] [Related]
10. Preclinical assessment of an anti-HTLV-1 heterologous DNA/MVA vaccine protocol expressing a multiepitope HBZ protein.
Daian E Silva DSO; Cox LJ; Rocha AS; Lopes-Ribeiro Á; Souza JPC; Franco GM; Prado JLC; Pereira-Santos TA; Martins ML; Coelho-Dos-Reis JGA; Gomes-de-Pinho TM; Da Fonseca FG; Barbosa-Stancioli EF
Virol J; 2023 Dec; 20(1):304. PubMed ID: 38115107
[TBL] [Abstract] [Full Text] [Related]
11. Multiple myeloma, haematologic malignancy and immunosuppressant and immunomodulatory medications are associated with sebaceous carcinoma, a pharmacovigilance study of the FDA adverse event reporting system.
Jedlowski PM; DuPont JP
J Eur Acad Dermatol Venereol; 2024 May; 38(5):937-944. PubMed ID: 38071595
[TBL] [Abstract] [Full Text] [Related]
12. Higher Expression of Human Endogenous Retrovirus-K was Observed in Peripheral B Lymphocytes of leukemia and Lymphoma Patients.
Li T; Qian K; Han J; Liu Y; Jia L; Wang X; Li T; Zhang B; Li J; Li H; Dou L; Li L
AIDS Res Hum Retroviruses; 2024 Apr; 40(4):268-279. PubMed ID: 38009220
[TBL] [Abstract] [Full Text] [Related]
13. [Effect of Human Bone Marrow Mesenchymal Stem Cells with Ectopic High OCT4 Expression on T Lymphocyte Function].
Guo XP; Chen YF; Chen P; Pan J; Ying PT; Zhao N; Tang YM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1523-1530. PubMed ID: 37846711
[TBL] [Abstract] [Full Text] [Related]
14. Th1/interferon-γ bias in 22q11.2 deletion syndrome is driven by memory T cells and exacerbated by IL-7.
Vladyka O; Vrabcova P; Reiterova M; Parackova Z; Haesler R; Sediva A; Kalina T; Klocperk A
Clin Immunol; 2023 Nov; 256():109793. PubMed ID: 37776967
[TBL] [Abstract] [Full Text] [Related]
15. Treg-targeted il-2/anti-il-2 complex controls graft-
Thiolat A; Pilon C; Caudana P; Moatti A; To NH; Sedlik C; Leclerc M; Maury S; Piaggio E; Cohen JL
Haematologica; 2024 Jan; 109(1):129-142. PubMed ID: 37706355
[TBL] [Abstract] [Full Text] [Related]
16. Adverse events and efficacy of second-round CAR-T cell therapy in relapsed pediatric B-ALL.
Ji Q; Wu X; Zhang Y; Zeng L; Dong Y; Liu R; Li B; Bai Z; Hu S; Lu J; Wu S
Eur J Haematol; 2024 Jan; 112(1):75-82. PubMed ID: 37649264
[TBL] [Abstract] [Full Text] [Related]
17. NKG2A gene variant predicts outcome of immunotherapy in AML and modulates the repertoire and function of NK cells.
Hussein BA; Kristenson L; Pesce S; Wöhr A; Tian Y; Hallner A; Brune M; Hellstrand K; Tang KW; Bernson E; Thorén FB
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37648262
[TBL] [Abstract] [Full Text] [Related]
18. HLA-B*44 and the Bw4-80T motif are associated with poor outcome of relapse-preventive immunotherapy in acute myeloid leukemia.
Komic H; Hallner A; Hussein BA; Badami C; Wöhr A; Hellstrand K; Bernson E; Thorén FB
Cancer Immunol Immunother; 2023 Nov; 72(11):3559-3566. PubMed ID: 37597015
[TBL] [Abstract] [Full Text] [Related]
19. Modulation of bone marrow and peripheral blood cytokine levels by age and clonal hematopoiesis in healthy individuals.
Ravalet N; Guermouche H; Hirsch P; Picou F; Foucault A; Gallay N; Martignoles JA; Beaud J; Suner L; Deswarte C; Lachot S; Rault E; Largeaud L; Gissot V; Béné MC; Gyan E; Delhommeau F; Herault O
Clin Immunol; 2023 Oct; 255():109730. PubMed ID: 37562724
[TBL] [Abstract] [Full Text] [Related]
20. Good manufacturing practice production of CD34
de Jonge PKJD; van Hauten PMM; Janssen LD; de Goede AL; Berrien-Elliott MM; van der Meer JMR; Mousset CM; Roeven MWH; Foster M; Blijlevens N; Hobo W; Fehniger TA; Jansen JH; Schaap NPM; Dolstra H
Cancer Immunol Immunother; 2023 Oct; 72(10):3323-3335. PubMed ID: 37477653
[TBL] [Abstract] [Full Text] [Related]
[Next]
